Ocular involvement in monkeypox: Description of an unusual presentation during the current outbreak - 13/10/22
Doi : 10.1016/j.jinf.2022.08.011
V Mazzotta a, A Mondi a, ⁎ 
, F Carletti b, F Baldini a, R Santoro c, S Meschi b, M Moccione a, S Gebremeskel Teklè a, C Minosse b, M Camici a, S Vita a, G Matusali b, E Nicastri a, E Girardi d, F Maggi b, F Vaia e, A Antinori a, 1, C Pinnetti a, 1
, F Carletti b, F Baldini a, R Santoro c, S Meschi b, M Moccione a, S Gebremeskel Teklè a, C Minosse b, M Camici a, S Vita a, G Matusali b, E Nicastri a, E Girardi d, F Maggi b, F Vaia e, A Antinori a, 1, C Pinnetti a, 1 a Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, Rome 00149, Italy
b Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
c Service of Ophthalmologist, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
d Scientific Direction, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
e General Direction, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
⁎Corresponding author.
Highlights |
• | In the current multinational outbreak of MPX, ocular complications have been reported very rarely compared with what has been reported in previous outbreaks in endemic settings. |
• | This is one of the first cases described of monkeypox (MPX) with ocular involvement with an infective and replication competent MPXV isolated in culture. |
• | The time-course of the ocular manifestations (ocular onset delayed with respect to the skin rash and concomitant systemic symptoms).is suggestive of a pathogenetic mechanism based on self-inoculation from skin lesions. |
• | Viral clearance and clinical recovery after treatment with intravenous Cidofovir were slow. |
Keywords : Monkeypox, MSM, Emerging infectious diseases, West African clade, Ocular lesions
Plan
© 2022
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 85 - N° 5
P. 573-607 - novembre 2022 Retour au numéro
Article précédent
- Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants
- Tetsuya Mizoue, Shohei Yamamoto, Maki Konishi, Yusuke Oshiro, Natsumi Inamura, Takashi Nemoto, Mitsuru Ozeki, Kumi Horii, Kaori Okudera, Haruhito Sugiyama, Nobuyoshi Aoyanagi, Wataru Sugiura, Norio Ohmagari
- Is SARS-CoV-2 an oncogenic virus?
- Alberto Gómez-Carballa, Federico Martinón-Torres, Antonio Salas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?